45 results
8-K
EX-99.1
ITCI
Intra-Cellular Therapies Inc
7 May 24
Intra-cellular Therapies Reports First Quarter 2024 Financial Results
7:40am
to $98.9 million for the same period in 2023.
Research and development (R&D) expenses were $42.8 million for the first quarter of 2024, compared to $38.0 … to $480 million and R&D expense guidance of $215 to $240 million reiterated.
CLINICAL HIGHLIGHTS
Lumateperone:
Adjunctive MDD program: Studies 501
8-K
EX-99.1
ITCI
Intra-Cellular Therapies Inc
22 Feb 24
Intra-cellular Therapies Reports Fourth Quarter and Full-year 2023 Financial Results and Provides Corporate Update
7:39am
. This increase is primarily due to an increase in commercialization, marketing and advertising costs.
Research and development (R&D) expenses were … and marketing activities.
R&D expenses for the full year 2024 are expected to be $215 to $240 million, including approximately $20 million of non-cash, share
8-K
EX-99.1
ITCI
Intra-Cellular Therapies Inc
2 Nov 23
Intra-cellular Therapies Reports Third Quarter 2023 Financial Results and Raises 2023 Caplyta Sales Guidance
8:01am
million for the third quarter of 2023, compared to $88.4 million for the same period in 2022.
Research and development (R&D) expenses were $41.6 million … to $470 million from the previous range of $445 to $465 million.
Full year 2023 SG&A expense guidance lowered to $405 to $420 million and R&D expense
8-K
EX-99.1
ITCI
Intra-Cellular Therapies Inc
3 Aug 23
Intra-cellular Therapies Reports Second Quarter 2023 Financial Results and Raises 2023 Caplyta Sales Guidance
7:39am
million for the second quarter of 2023, compared to $100.3 million for the same period in 2022.
Research and development (R&D) expenses were $49.8 … &A expense guidance of $420 to $450 million and R&D expense guidance of $195 to $220 million reiterated.
CLINICAL HIGHLIGHTS
Lumateperone
8-K
EX-99.1
mbsl16
4 May 23
Intra-cellular Therapies Reports First Quarter 2023 Financial Results and Provides Corporate Update
7:37am
8-K
EX-99.1
oh8bs9ijk sg9g9f
3 Nov 22
Intra-cellular Therapies Reports Third Quarter 2022 Financial Results and Provides Corporate Update
7:35am
8-K
EX-99.1
9n63jjn2 m6rccw0e
9 Aug 22
Intra-cellular Therapies Reports Second Quarter 2022 Financial Results and Provides Corporate Update
7:38am
8-K
EX-99.1
1hf9tx
10 May 22
Intra-cellular Therapies Reports First Quarter 2022 Financial Results and Provides Corporate Update
7:37am
8-K
EX-99.1
40u657xr
1 Mar 22
Intra-cellular Therapies Reports Fourth Quarter and Full-year 2021 Financial Results and Provides Corporate Update
7:49am
8-K
EX-99.1
bl5up3h
9 Nov 21
Intra-cellular Therapies Reports Third Quarter 2021 Financial Results and Provides Corporate Update
7:49am
8-K
EX-99.1
b8dli x4knc9m
9 Aug 21
Intra-cellular Therapies Reports Second Quarter 2021 Financial Results and Provides Corporate Update
7:37am
8-K
EX-99.1
ywx3r1y
10 May 21
Intra-cellular Therapies Reports First Quarter 2021 Financial Results and Provides Corporate Update
7:37am
8-K
EX-99.1
zspr4
25 Feb 21
Intra-cellular Therapies Reports Fourth Quarter and Full-year 2020 Financial Results and Provides Corporate Update
7:54am
8-K
EX-99.1
zvxtm4yt6khuoze 6v4
9 Nov 20
Intra-cellular Therapies Reports Third Quarter 2020 Financial Results and Provides Corporate Update
7:40am
8-K
EX-99.1
8vc ot5og5e9sxb9uk
10 Aug 20
Intra-cellular Therapies Reports Second Quarter 2020 Financial Results and Provides Corporate Update
7:52am
8-K
EX-99.1
rae8 7ahmy65tos4e9b
7 May 20
Intra-cellular Therapies Reports First Quarter 2020 Financial Results and Provides Corporate Update
7:42am